How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer’s disease?

Introduction Monoclonal antibodies targeting amyloid-β are the first disease-modifying treatments for Alzheimer disease to have received FDA-approval. There are three different drugs approved or pending FDA-approval: aducanumab, lecanemab, and donanemab. These three drugs are each in different stages of regulatory approval by the FDA.